Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

2 recruiting4 with results

Enrollment Performance

Analytics

Early Phase 1

3(37.5%)

Phase 2

2(25.0%)

Phase 4

2(25.0%)

N/A

1(12.5%)

8Total

Early Phase 1(3)

Phase 2(2)

Phase 4(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04666636Phase 2Recruiting

Mechanisms for Activation of Beige Adipose Tissue in Humans

Role: lead

NCT05051436Phase 4Recruiting

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

Role: lead

NCT02596776Early Phase 1Completed

Cold Induced Changes in White Adipose

Role: lead

NCT02919176Early Phase 1Completed

Brown Fat Activation Study

Role: lead

NCT02308228Early Phase 1Completed

Metformin to Augment Strength Training Effective Response in Seniors (MASTERS)

Role: lead

NCT02124512Phase 2Completed

Blood Lipopolysaccharide (LPS) Rifaximin Study

Role: lead

NCT00579436Not ApplicableCompleted

Effects of Fish Oils on Inflammation and Insulin Resistance

Role: lead

NCT00579813Phase 4Completed

Mechanisms Underlying Metabolic Syndrome in Obesity

Role: lead

All 8 trials loaded